DISSERTATION

To Understand the Regulatory Role of miRNA and its Targets

Submitted to
 Amity University Uttar Pradesh
In partial fulfilment of the requirements for the award of the degree of
MSc. Biotechnology

By

Shraddha Dubey
Enrolment No. – A0500223077

MSB/23/174
(Semester-IV)

Under the guidance of

Prof. (Dr.) Amit Kumar

Chaurasia Amity Institute of
Biotechnology Amity University
Uttar Pradesh
2023-2025

Signature of NTCC Convener

AMITY INSTITUTE OF BIOTECHNOLOGY

 CERTIFICATE BY IFC

On the basis of declaration submitted by Shraddha Dubey, student of [Link].

Biotechnology, I hereby certify that the dissertation titled “To Understand the
Regulatory Role of miRNA and its Targets” which is submitted to Amity Institute of
Biotechnology, Amity University Uttar Pradesh, in partial fulfilment of the
requirement for the award of the degree of [Link]. Biotechnology, is an original
contribution with existing knowledge and faithful record of work carried out by her.
To the best of my knowledge this work has not been submitted in part or full for any
Degree or Diploma to this University or elsewhere.

Place : Noida
Date :

3
AMITY INSTITUTE OF
BIOTECHNOLOGY

PLAGIARISM
CERTIFICATE

4
Signature of the NTCC
This is to certify that the thesis Coordinator
entitled To Understand the Dr. Ritu Chauhan
Regulatory Role of miRNA and its
Targets submitted by Shraddha
Dubey for the partial fulfilment of the
degree of [Link]. Biotechnology has
been checked by Turnitin software
for plagiarism.

The thesis has 10% percent

plagiarism.

Signature of the IFC

Prof. (Dr.) Amit Kumar
Chaurasia
8% Internet sources
0% Publications

7% Submitted works (Student

Papers)

Integrity Flags

0 Integrity Flags for Review

No suspicious text manipulations found

6
 AMITY UNIVERSITY
-----UTTAR PRADESH-----
Amity Institute of Biotechnology

Dissertation
Stud
ent
SHRADDHA DUBEY
Nam
e
Enro
llme
A0500223077
nt
No
Prog
ram [Link]. (Biotechnology)
me
Com Amity University
pany
's
Nam
e
and Sector 125, Noida, Uttar
Add
ress
Pradesh 247776
Industry Guide
Nam
Dr. Amit Kumar Chaurasia
e
Desi
gnati Professor
on
Contact Number
Ph.(O) : 9415853361 (R) : 9415853361
Mobile : 9415853361
Fax : +91-0120 4392947
E-mail : akphaurasia@[Link]

Project Information

1) Project Duration : (126 Days)

a) Date of Summer Internship commencement (17/12/2024)
a) Date of Summer Internship Completion (19/05/2025)
2) Topic

To Understand the Regulatory Role of miRNA and its Targets

 3) Project Objective

The primary objective of this project is to investigate the regulatory role of

microRNAs (miRNAs) and their specific target genes to better understand
their function in gene expression modulation. miRNAs are small non-coding
RNAs that play a crucial role in post-transcriptional regulation by binding to
complementary sequences on target mRNAs, leading to mRNA degradation
or translational repression.
This project aims to identify key miRNAs involved in a specific biological
context and predict their target genes using bioinformatics tools.
Experimental validation through molecular techniques will be used to
confirm the interaction between selected miRNAs and their targets. By
analyzing the expression profiles and regulatory impact of miRNAs, the
study seeks to elucidate their role in controlling cellular pathways and
physiological processes. The findings from this research may contribute to a
deeper understanding of gene regulatory networks and provide insights into
the potential use of miRNAs as biomarkers or therapeutic targets

4) Methodology to be adopted
1. Sample Collection and RNA Isolation,

2. miRNA Expression Analysis,

3. Bioinformatics Prediction of miRNA Targets,

4. Validation of miRNA-Target Interaction,

5. Gene Expression Analysis,

6. Data Interpretation and Statistical Analysis

5) Brief Summary of project(to be duly certified by the industry guide)

This dissertation explores the enzymatic valorization of sugarcane-derived residues such as bagasse, molasses,
and press mud into value-added products. Enzymes like cellulases, xylanases, and ligninases play a central role
in breaking down complex biomass under environmentally friendly conditions. The research highlights the
advantages of enzymatic bioconversion over traditional chemical methods, including lower energy
requirements, reduced emissions, and product specificity. Special attention is given to enzyme immobilization
and pretreatment techniques that enhance efficiency and reusability. The findings demonstrate that enzymatic
processing can transform agro-industrial waste into commercially viable bioproducts, supporting India's
circular economy and green energy goals.
Signature

Signature

8
(Student) guide) (Faculty
9
10

11
 AMITY INSTITUTE OF BIOTECHNOLOGY

ACKNOWLEDEGEMENT

I would like to express my heartfelt gratitude to Prof. Dr. Amit Kumar Chaurasia for his invaluable guidance and
constant support throughout my dissertation. His expert advice, thoughtful insights, and continuous
encouragement played a crucial role in the successful completion of my project. I am truly thankful for the time
and effort he dedicated not only to my research work but also to advising me on future academic and
professional directions.

I would also like to thank all the faculty members, batchmates, and seniors of Amity Institute of
Biotechnology, Amity University Uttar Pradesh for their unwavering support, motivation, and helpful
suggestions during the course of my project.

Shraddha Dubey

A0500223077

12
 TABLE OF CONTENTS

Page No.
[Link]. Chapter

1 Declaration 2

2 Certificate by IFC 3

3 Plagiarism certificate 4

4 Synopsis 6

5 Certificate by Faculty 8

6 Acknowledgment 9

7 Table of contents 10

8 List of Figures 11

9 List of Tables 11

10 List of graphs 11

11 Abstract 12

12 Introduction 14

13 Review of literature 18

14 Aim and objective 40

15 Materials and methodology 41

16 Results 43

17 Conclusion 46

18 References 47
13

LIST OF FIGURES

[Link] Title of Figure Page No.

.
33
1 Workflow of Bagasse to Bioethanol
33
2 Workflow of Molasses to Organic Acids
 34
3 Workflow of Press Mud to Biogas
43
4 Sugarcane Farming in Uttar Pradesh
LIST OF TABLES

[Link] Title of Table Page No.

.
Key Enzymes Involved in Lignocellulosic Hydrolysis and Their 41
1
Applications
45
2 Value-Added Products from Sugarcane Waste
LIST OF GRAPHS

.
[Link] Title of Graph Page No.
.
15
1 Sugarcane processing components
44
2 Composition comparison of Bagasse, Molasses and Press Mud
14

Abstract

MicroRNAs (miRNAs) are a large and diverse class of small, non-coding RNA molecules that play a critical role
in the post-transcriptional regulation of gene expression across all multicellular organisms. Although miRNAs do
not encode proteins themselves, they exert significant control over protein synthesis by guiding cellular machinery
in determining which proteins to produce or suppress. This regulation is primarily achieved through gene silencing
mechanisms. By binding to complementary sequences within the 3' untranslated regions
(3' UTRs) of target messenger RNAs (mRNAs), miRNAs can trigger either the degradation of the mRNA or the
inhibition of its translation, thereby fine-tuning protein production within the cell.

It is estimated that approximately 30% of gene expression in the human genome is regulated by miRNAs,
highlighting their widespread and vital influence on cellular processes. miRNAs are known to be essential
regulators of various biological activities, including cell proliferation, differentiation, development, apoptosis, and
metabolism. Furthermore, dysregulation of miRNA expression and function has been implicated in the
pathogenesis of several diseases, such as cancer, neurodegenerative disorders, and cardiovascular conditions.
Due to their stability in biological samples and their disease-specific expression patterns, miRNAs have emerged
as promising biomarkers for early diagnosis, prognosis, and potential therapeutic targets.

Despite the extensive progress made in understanding miRNA biology, many aspects of their regulatory
mechanisms, target specificity, and functional consequences remain elusive. In this study, we aim to delve deeper
into the molecular mechanisms underlying miRNA-mediated gene regulation, with a particular focus on their
interactions with target mRNAs and the downstream effects on gene expression. By advancing our understanding
of miRNA regulatory networks, this work seeks to contribute valuable insights into the broader landscape of gene
regulation and its implications in health and disease.

15

Introduction
The miRNA

MicroRNAs (miRNAs) are a well-studied class of endogenous, small non-coding RNA molecules that are
typically 21 to 25 nucleotides in length and play a pivotal role in regulating gene expression at the post-
transcriptional level. Their discovery in Caenorhabditis elegans in the early 1990s marked a paradigm shift in
molecular biology. The first miRNA, lin-4, was identified in 1993 and shown to regulate the timing of larval
development by repressing the expression of the lin-14 gene through base-pairing to sequences in the 3′
untranslated region (UTR) of its mRNA. Several years later, another miRNA, let-7, was discovered and found to be
conserved across a wide array of animal species, including humans, suggesting a broad and essential role for
miRNAs in gene regulation throughout evolution. This conservation of function pointed to the likelihood that
miRNAs were a universal mechanism employed across metazoans to regulate developmental timing and other
critical processes. Soon after these foundational discoveries, high-throughput sequencing and cloning methods led
to the identification of hundreds of additional miRNAs in species ranging from flies to mammals. It became clear
that miRNAs are a highly abundant and diverse group of regulatory RNAs, functioning in nearly every cellular
process, including differentiation, proliferation, apoptosis, and metabolism.

The biogenesis of miRNAs is a multistep process involving both nuclear and cytoplasmic machinery. Initially,
miRNA genes are transcribed by RNA polymerase II into long primary transcripts called pri-miRNAs, which are
often capped and polyadenylated like typical messenger RNAs. These pri-miRNAs fold into hairpin loop
structures and are recognized and cleaved in the nucleus by the Microprocessor complex, which consists of the
RNase III enzyme Drosha and its essential cofactor DGCR8 (DiGeorge Syndrome Critical Region 8). This
processing results in the production of precursor miRNAs (pre-miRNAs), which are approximately 70 nucleotides
in length and still retain a stem-loop structure. These pre-miRNAs are then transported from the nucleus to the
cytoplasm by Exportin-5, a Ran-GTP-dependent nuclear transport receptor. Once in the cytoplasm, the enzyme
Dicer, another RNase III-type endonuclease, cleaves the pre-miRNA near the loop region to generate a short
double-stranded RNA molecule. One strand of this duplex, referred to as the guide strand, is preferentially loaded
into the Argonaute (AGO) protein, a core component of the RNA-induced silencing complex
(RISC), while the other strand, known as the passenger strand, is typically degraded.
Once incorporated into the RISC complex, the mature miRNA guides the complex to complementary sequences in
target mRNAs, predominantly in the 3′ untranslated regions, where it exerts its regulatory effects. The degree of
complementarity between the miRNA and its target determines the mechanism of gene silencing. In cases of near-
perfect base pairing, which is more common in plants, the miRNA directs the cleavage and subsequent degradation
of the target mRNA. In animals, however, the pairing is usually imperfect, leading to translational repression,
mRNA deadenylation, and decapping, eventually causing destabilization and degradation of the mRNA. This
allows miRNAs to fine-tune protein production rather than completely silence gene expression. It is estimated that
more than 60% of human protein-coding genes are under selective pressure to maintain miRNA binding sites,
which underscores the vast regulatory capacity of miRNAs in human cells.

16

Functionally, miRNAs are involved in a wide variety of biological and developmental processes.
They play critical roles in embryogenesis, stem cell maintenance, tissue differentiation, and organ development. In
the immune system, miRNAs regulate both innate and adaptive responses by modulating the expression of
cytokines, receptors, and transcription factors. They are also essential for maintaining homeostasis and preventing
diseases. Dysregulation of miRNA expression has been implicated in numerous pathological conditions, including
various types of cancer, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases. For
instance, some miRNAs act as tumor suppressors by inhibiting oncogene expression, while others may function as
oncogenes (oncomiRs) by repressing tumor suppressor genes. The miR- 17-92 cluster, for example, is often
overexpressed in cancers and contributes to cell cycle progression and inhibition of apoptosis. Conversely, loss of
function in tumor-suppressive miRNAs like let-7 can lead to unchecked cell proliferation and tumorigenesis.

Due to their stability in blood and other body fluids, miRNAs are also being explored as potential biomarkers for
disease diagnosis and prognosis. Circulating miRNAs can be detected noninvasively, making them attractive
candidates for early detection and monitoring of disease progression. Furthermore, therapeutic strategies involving
miRNAs are being actively pursued.
These include miRNA mimics, which aim to restore the function of downregulated miRNAs, and miRNA
inhibitors or antagomirs, which suppress the activity of overexpressed or harmful miRNAs. Several miRNA-based
therapeutics have entered clinical trials, particularly in the field of oncology, offering hope for new targeted
treatments with minimal off-target effects.

In summary, microRNAs represent a fundamental layer of gene regulation with wide-reaching impacts on cellular
function and organismal development. Their unique biogenesis from hairpin- forming transcripts, combined with
their incorporation into the RISC complex and ability to repress gene expression post-transcriptionally,
distinguishes them from other classes of small RNAs such as siRNAs and piRNAs. The widespread conservation,
abundance, and functional diversity of miRNAs underscore their importance in biology and medicine. Ongoing
research continues to unravel new roles of miRNAs in health and disease, and their potential as diagnostic and
therapeutic tools is being realized with increasing clarity. As high-throughput sequencing and computational
analysis methods improve, we are likely to discover even more miRNAs and deepen our understanding of this vital
class of regulatory RNAs.

The biogenesis of microRNAs

MiRNAs function by decreasing translational efficiency and/or mRNA levels. They originate as primary miRNA
(pri-miRNA), which are initially transcribed as double-stranded sequences with a hairpin structure. These pri-
miRNAs are cleaved by the Drosha/DGCR8 endonuclease complex, resulting in the formation of precursor
miRNA (pre-miRNA). The pre-miRNAs are then transported to the cytoplasm via a binding protein named
Exportin 5. In the cytoplasm, pre- miRNAs are further cleaved by the DICER endonuclease, forming mature
double-stranded miRNAs. Subsequently, these strands are separated, and the functional strand is incorporated into
the RNA-induced silencing complex (RISC), which includes proteins such as including Argonaut 2 (AGO-2).
When RISC binds to the 3′ untranslated region (3′ UTR) of a target mRNA, it triggers deadenylation by
exonucleases. This mechanism ultimately results in the regulation of gene expression.

17
A functional miRNA that can control gene expression is created by a multi-step process called
microRNA (miRNA) biogenesis, which starts in the nucleus and ends in the cytoplasm. RNA
polymerase II first transcribes miRNAs as pri-miRNAs, which are lengthy initial transcripts that have
the ability to create distinctive stem-loop structures. The Microprocessor complex, which is made up of
the RNase III enzyme Drosha and its cofactor DGCR8, breaks down these pri- miRNAs in the nucleus
into shorter precursor miRNAs, or pre-miRNAs, of roughly 70 nucleotides. Exportin-5 then transports
the pre-miRNAs to the cytoplasm in a way that is dependent on Ran- GTP.

A ~22-nucleotide miRNA duplex is created in the cytoplasm when the pre-miRNA is cleaved by
another RNase III enzyme called Dicer. Within the RNA-induced silencing complex (RISC), one strand
of this duplex—referred to as the guide strand—is loaded onto the Argonaute protein, whilst the other
strand—referred to as the passenger strand—is usually broken down. After being integrated into RISC,
the mature miRNA directs the complex to complementary sequences in target mRNAs, which results in
mRNA destruction or translational repression, post- transcriptionally controlling gene expression.
 18

The biogenesis of miRNAs begins with transcription of primary miRNA (pri-miRNA) by RNA Polymerase II,
followed by cleavage of pri-miRNA by DROSHA endonuclease, forming a precursor miRNA (pre- miRNA). The
pre-miRNA is transported to the cytoplasm by the exportin 5 complex. In the cytoplasm the pre-miRNA is
cleaved by another endonuclease, DICER, forming a miRNA duplex. The strands are separated by argonaut
complex, and the single strand is considered the mature miRNA, which together with the RNA-induced silencing
complex (RISC), binds to the target mRNA leading to repression of translation or degradation of mRNA. The
binding of the seed region of miRNAs to complementary
sequences in the 3′ UTR of target mRNAs inhibits gene expression at the post- transcriptional
level. Different approaches for analyzing miRNAs aim to predict the potential to inhibit target genes by
considering factors such as base pair similarity, algorithmic predictions, and conservation of target sites.
Additionally, these methods assess the association of target genes with different biological processes and diseases.
Since many miRNAs are conserved across different species, they play crucial roles in development and the
regulation of homeostasis. Indeed, without miRNAs, animals and plants would be unable to survive or reproduce.
The recognition of miRNAs as key post-transcriptional regulators has led to significant clinical applications.
 19

Classification of miRNA
There are over 2,600 mature human miRNAs identified and annotated.

 Human (Homo sapiens):

o 1,917 precursor miRNAs (hairpin structures)
o 2,654 mature miRNAs (functional strands)

These miRNAs are classified based on their origin, structure, and function.

Types/Categories

A-Canonical miRNA-

The most well-established and typical biogenesis process is followed by canonical miRNAs. The two
main enzymes involved in this process are Drosha and Dicer, which transform miRNA from a primary
transcript into a mature, functional form in a stepwise manner.
Biogenesis Pathway:

1. Transcription of miRNA Genes

miRNA manufacturing starts in the nucleus, where RNA Polymerase II mainly transcribes miRNA
 genes, however occasionally RNA Polymerase III may also play a role. Primary microRNAs (pri-
miRNAs) are big RNA molecules produced as a result of these transcription events. Several hundred to
thousands of nucleotides can make up these pri-miRNAs, and they frequently have one or more stem-
loop structures that are necessary for the subsequent processing stages.
The pri-miRNAs have a 3' poly(A) tail and a 5' cap, just like messenger RNAs (mRNAs).
miRNAs are frequently found co-transcribed with their host genes in the introns of either protein-coding
or non-coding genes. Conversely, intergenic miRNAs are transcribed without the assistance of their own
promoter [Link] factors, chromatin alterations, and epigenetic regulators all have a strong
influence on the transcriptional regulation of miRNA genes. This guarantees that miRNA expression is
precisely adjusted based on the tissue type, developmental stage, and nuclear cellular circumstances.
[Link] of pri-miRNA to pre-miRNA

Following transcription, the pri-miRNA is processed in the nucleus to create the precursor miRNA (pre-
miRNA), a shorter hairpin-shaped intermediate. A microprocessor complex made up of two primary
proteins mediates this crucial step.

 Drosha: An RNase III enzyme responsible for cleaving double-stranded regions of RNA.
 DGCR8 (DiGeorge syndrome critical region 8): An RNA-binding protein that recognizes and binds to
the double-stranded stem-loop of the pri-miRNA, guiding Drosha to the correct cleavage site.

20

The shorter, hairpin-shaped intermediate known as the precursor miRNA (pre-miRNA) is created by the
nucleus processing the pri-miRNA following transcription. A microprocessor complex made up of two
primary proteins mediates this crucial step, Errors or mutations in Drosha or DGCR8 can lead to
atypical miRNA maturation, which has been connected to a variety of diseases, including cancer and
neurodevelopmental issues.

3. Export of pre-miRNA from Nucleus to Cytoplasm

The pre-miRNA needs to be moved from the nucleus to the cytoplasm for further maturation after
nuclear processing. A specific transport protein called Exportin-5, a member of the karyopherin family
of nuclear transport receptors, facilitates this procedure. When Ran-GTP, a little GTP- binding protein,
is present, exportin-5 forms a complex with the pre-miRNA's 2- nucleotide 3' overhang. The pre-
miRNA is delivered into the cytoplasm by this ternary complex translocating through the nuclear pore
complex. After entering the cytoplasm, the complex disassembles and the pre-miRNA is released when
the GTP is hydrolyzed to GDP. Pre-miRNAs are protected from degradation during transport by
exportin-5, which also guarantees their unidirectional mobility. Maintaining the stability and abundance
of miRNA in the cell depends on this phase.
4. Cytoplasmic Processing into Mature miRNA Duplex

The Dicer enzyme, another RNase III-type endonuclease, catalyzes the second cleavage step that the
pre-miRNA passes through in the cytoplasm. Dicer identifies the pre-miRNA's terminal loop and
cleaves it close to the stem's base, creating a ~22-nucleotide miRNA duplex with two strands:
• The functional miRNA, or guide strand
• The passenger strand, also known as miRNA* and typically degrades

RNase III-mediated processing is indicated by the 2-nucleotide overhangs at both 3' ends of this duplex.
The mature miRNA's capacity to target particular mRNAs depends critically on its exact length and
 sequence. In certain situations, Dicer also interacts with other proteins that aid in miRNA loading and
strand selection, such as PACT or TRBP (TAR RNA-binding protein).
5. RISC Loading and Gene Silencing

The miRNA duplex is put into the RNA-induced silencing complex (RISC) after cytoplasmic
processing. Argonaute (AGO) proteins, which are crucial for mediating the gene-silencing effects of
miRNAs, are present in this complex. The RISC machinery preferentially incorporates the strand with
the less stable 5' end as the guide strand during loading after assessing the thermodynamic stability of
the duplex ends. In rare instances, the other strand—usually the passenger strand—is either destroyed or
kept as a functioning miRNA. The mature miRNA directs the complex to complementary sequences in
the target mRNAs' 3' untranslated regions (3' UTRs) once it has been integrated into RISC. Two main
results could arise, depending on the level of sequence complementarity:
• mRNA degradation: AGO2 mediates mRNA cleavage when base pairing is nearly perfect,
which is typical in plants.

21

• Translational repression and mRNA destabilization: The target mRNA's translation is

suppressed and may ultimately breakdown if complementarity is partial, which is typical
in animals.
Through this mechanism, miRNAs work as post-transcriptional regulators, modifying the expression of
genes related to cell cycle, apoptosis, development, differentiation, and several other cellular processes.

B. Non-Canonical miRNAs

Alternative pathways that diverge from the Drosha-Dicer route are used to process non-canonical
miRNAs. They may omit stages entirely or employ other enzymes. There are some Subtypes of
Non- Canonical miRNAs.

(1) Mirtrons

Definition and Origin:

Mirtrons are a unique class of non-canonical miRNAs that are derived directly from intronic regions
of pre-mRNA [Link] serve as a functional connection between miRNA biogenesis and the splicing
mechanism. Mirtrons completely avoid the microprocessor complex and use the cell's own splicing
processes to start their maturation rather than needing Drosha- mediated cleavage for initial processing.

Biogenesis Mechanism:
[Link]: Mirtrons are incorporated into host gene introns. After transcription, the host pre- mRNA is
subjected to splicing, which results in the removal of introns as lariat structures.
2. Debranching and Folding: Lariat debranching enzymes then debranche the lariat intron, turning it
into
a
linear
molecule.
3. Hairpin Formation: Like classical pre-miRNAs, the linear intron folds into a hairpin structure that
resembles
a
pre-miRNA.
4. Export and Dicer Processing: Exportin-5 exports this hairpin to the cytoplasm, where it undergoes processing by Dicer
to produce a mature miRNA duplex.
Functional Significance:
• By combining miRNA synthesis and splicing, mirtrons provide close coordination between miRNA control and
gene expression. Cells with decreased Drosha activity might use this route as fallback.
• As an illustration of their evolutionary conservation, certain mirtrons have been found in humans, C. elegans, and
Drosophila melanogaster.
Implications in Disease:
• Aberrant miRNA levels may result from splicing factor or mitochondrial processing dysregulation, which may
exacerbate illnesses including cancer and neurological conditions.

22

(2) snoRNA-Derived miRNAs

Definition and Origin:

Dysregulation of mitochondrial processing or splicing factors may lead to aberrant miRNA levels, which can
worsen diseases like cancer and neurological disorders.

Mechanism Biogenesis:

1. Transcription and Processing: The nucleus is where snoRNAs are first transcribed
and processed, after which they gather in nucleoli.
2. Cleavage: Dicer or endonucleases break down some snoRNAs to create ~22 nucleotide RNA fragments that
resemble mature miRNAs.
3. Function: To control gene expression, these processed fragments can join the RISC complex and attach to
Argonaute proteins.

Functional Significance:
• This mechanism demonstrates the multipurpose character of non-coding RNAs, showing that
RNA molecules can have overlapping roles in several regulatory systems.
• miRNAs produced from snoRNA may target mRNAs for translational inhibition or destruction.
• miRNAs produced from snoRNA may have a role in cell growth, proliferation, and stress responses.
Example:
It has been demonstrated that certain C/D box snoRNAs in mammals generate regulatory RNAs with miRNA-like
properties.
Implications in Disease:
Cancer, particularly hematological malignancies like leukemia, has been linked to abnormal snoRNA expression
or processing. These abnormalities are being investigated as possible indicators for illness diagnosis and prognosis.
3) tRNA-Derived miRNAs (tRFs)

Definition and Origin:

During protein synthesis, transfer RNAs (tRNAs), which are crucial parts of the translational machinery, are in
charge of transferring amino acids to the ribosome. Remarkably, tRNA-derived fragments (tRFs), which are
fragments formed from tRNAs, have been identified as a distinct class of small regulatory RNAs with miRNA-like
functions.
Biogenesis Mechanism:

[Link]: Under specific physiological or stress conditions, mature tRNAs or pre-tRNAs are cleaved by enzymes such
 as angiogenin or Dicer to generate short RNA fragments.

23

Fragment Types:

tRF-5s: Derived from the 5’ end of tRNAs.


 tRF-3s: Derived from the 3’ end.
 tRF-1s: Derived from the 3’ trailer sequence of pre-tRNAs.
 tRNA halves: Larger fragments produced during stress responses.

[Link]: Some tRFs associate with Argonaute proteins and can enter the RISC complex, where they function
similarly to canonical miRNAs.

Functional Significance:
• Through sequence complementarity or interactions with translation initiation complexes, tRFs control the
stability and translation of mRNA.
• They play a role in many different biological functions, such as immunological control, stress response, and cell
proliferation.
• Transgenerational epigenetic inheritance, especially in sperm cells, may also be influenced by tRFs.

Example:
• Specific tRFs have been found to suppress cancer cell proliferation and modulate gene expression during viral
infections.
Implications in Disease:
Because of their stability and abundance, tRFs are interesting candidates for both diagnostic and therapeutic uses.
Alternate tRF expression has been linked to cancer, metabolic illnesses, and neurodegenerative disorders.

Significance:
• Frequently control particular cellular processes and stress reactions.
• Functionally substantial yet less common.
• Describe the versatility of RNA processing.
Example:

miR-320 (produced through Dicer-dependent but Drosha-independent pathway)

 24

C. Intronic vs Intergenic miRNAs

1. Intronic miRNAs

These miRNAs are located within the introns of protein-coding or non-coding host genes.

Characteristics:

 Often co-expressed with their host gene.

 May or may not regulate the host gene.
 Can use the splicing machinery for processing (especially mirtrons).

Significance:

 Contribute to regulatory complexity within genes.

 Can coordinate regulation of multiple gene products from a single locus.

2. Intergenic miRNAs

These miRNAs are found in intergenic regions (between genes) and are transcribed independently.

 Have their own promoters and regulatory elements.

 Transcribed similarly to independent protein-coding genes.

Significance:
• Permit autonomous and targeted regulation.
• Capable of forming miRNA clusters, which are collections of polycistronic transcripts.
D. Tissue-Specific miRNAs

These miRNAs exhibit restricted expression patterns, being predominantly or exclusively found in
certain tissues or cell types.
Examples:

 miR-122: Liver-specific; regulates lipid metabolism.

 miR-124: Brain-specific; involved in neuronal differentiation.
 miR-1: Muscle-specific; important in cardiac and skeletal muscle development

Significance:

They are vital for tissue identity and precise development, act as biomarkers for diseases specific to
particular tissues, and are frequently the cause of pathological conditions (e.g., neurological disorders,
liver cancer) when disturbed.

25
 E. OncomiRs and Tumor Suppressor miRNAs
1. OncomiRs (Oncogenic miRNAs)

These miRNAs promote cancer development and progression by downregulating tumor suppressor genes.

Mechanisms:

Enhance cell proliferation.

 Inhibit apoptosis.
 Facilitate angiogenesis and metastasis.

Example:

miR-21: Overexpressed in various cancers; targets PTEN and other tumor suppressors.

2. Tumor Suppressor

miRNAs Definition:

These miRNAs prevent tumor formation by targeting oncogenes and controlling cell growth.

Mechanisms:

 Inhibit cell cycle progression.

 Induce programmed cell death.
 Maintain genomic stability.

Example:

 let-7 family: Suppresses Ras oncogene; downregulated in many cancers.

26

Material Methods-
Amplicillin preparation: (100mg/ml) stock
  1.5 ml autoclaved MCTS
 0.2micron filter
 2ml/5ml syringe
 RNAase free water / NFW (Nuclease free water)

1. Measure empty1.5 MCT on weigh balance

and tare. Measure 100mg in MCT.

2. Add 1 ml NFW water.

3. Filter sterilize using 0.2 micron filter and

2ml syringe in fresh 1.5 MCT.

Aliqout in required no. of MCTS, divide

4.
volume equally.

1. Store in -20 for future use.

LB agar plate preparation for 1 plate:

 Petri plate
 LB agar autoclaved
 Cotton plug
 Conical flask
 Ampicilin

1).Add 0.4g of LB agar in 10ml autoclaved distilled

water and autoclave again. (for 40 ml,1.6g
LB agar is needed)

(Note: calculated based on 40g for 1L. It can be done in

bottle or conical flask, make
sure it is covered with Al foil)

2).Let LB agar sol, cool down in the hood, half way down the
temp, keep swirling once every 5 mins to avoid clumping at the
bottom

3).After the temp comes to a tolerable range, pour it on the petri-

dish 10ml/ plate. (75mm)
4).For transformation LB agar plates, add 1% of Ampicillin (amp)
based on the volume you required for no. of plates needed. 30ul
amp in 30ml of LB agar, 10ml each plate. So 1% per plate.

27
 5).Cover the petri plate with its lid half, to avoid any other particles falling on to it. Let it solidify inside the hood itself
15-20mins.
6).Can be used immediately after solidifying or can be parafilmed, wrapped in al foil in inverted manner and stored at 4
˚C for future use.

Observations 24/1/25
Made 1 plate without ampicillin for DH5α and 3 with ampicillin for transformation.

Streaking of DH5α cells on the LB agar plate

1. Allow the without ampicillin LB agar plate to reach room temperature (RT) from 40°C before use.
2. Add 10-20ul (conc) pre-cultured or glycerol stock [Link] (DH5α )cells on to the LB agar plate and streak
using 20-200ul tip.
(Note: volume of cells taken should be taken in a way that, cells can be covered whole plate for
streaking).
3. Incubate overnight @ 37 ˚C (16h min), by placing it in incubator in inverted manner.
(Note: no shaking needed)

28
 1. After incubation, next day keep it in 4 ˚C for longer storage.
(Note: should not keep it more than overnight, it may over populate & cell death, strain change.
To avoid this, after overnight incubation parafilm the petri-plates and wrap it up with Al foil)
2. Once the bacterial colonies have grown on the LB agar plate, they can be used for the primary culture.

Preparation of Competent cells

Materials Required:

 Competent Cells ([Link](DH5α))

 LB broth media (3.7g + 100ml autoclaved water)
 LB agar media
 Petridish for culture
 Autoclaved Conical flask/Falcon for culture
 Antibiotic (Ampicillin)
 100mM CaCl2 (1.11 g + 100 ml, autoclave)
 20% glycerol (final conc)

1 One denser colony of DH5α cells was picked from pre-cultured agar plate and
.
suspended in 5mL of LB broth, and kept for over-night incubator shaker at 37˚C.
(Note: this is our primary culture after overnight incubation. Look for the turbidity in the culture
media, which implies there is cell growth in the media.)
3. 0.5 ml of primary culture was taken and added to 50 ml of LB broth, kept it for 37˚C for
1 hour (approx. 3-4 hrs) with shaking 220 rpm.
(Note: Secondary culture was prepared in 50 mL of LB broth in a clean autoclaved 250ml flask.)
3. Take O.D at 600nm. Incubate till the O.D reached 0.3- 0.4.
(Note: while taking OD, one cuvette should be LB broth (blank) and other cuvette with comp
cells.)
4. The cells were then centrifuged at 4,000 rpm for 10 minutes at 4˚C.
Centrifuge at 4,000 rpm for 10 mins at 4˚C.
5 Supernatant was discarded and 10 mL of 100mM CaCl2 was added and cells were re- suspended.
.

29
6. Cells were then incubated at 4˚C for one hour on ice.
Incubate at 4˚C for 1 hr.
7. Centrifuge at 4,000 rpm for 10 minutes for 4˚C
8. To the pellet, 5 mL of 100mM CaCl2
which contain 20% glycerol added
re-suspended.
and the pellet
Resuspend pellet in 4ml of 100mM chilled CaCl2+20%
(1ml) glycerol.
(Note: add glycerol with cut tip)
9. Make aliquots of 50ul each in pre-chilled MCTs.
Store it in -80.
(Note: 0.6 ml MCT autoclaved)
30
Observations for this experiment (29/1/25)
 DH5α has borrowed from Kajal Kanchan ma’am
 It takes 1hr 20 mins to get 0.4 OD. Within 1 hr we get 0.2 OD as it gets 0.2 OD, it shoots up fast as it enters
from lag phase to log phase.
 Autoclaved glycerol is 100%
 Pre-culture glycerol stocks were made 50% glycerol in final conc, meaning if 1 ml stock is made 500ul pre-
culture+500ul glycerol.
 85 gylcerol stocks were made.50ul each.

31
 Transformation

Materials Required:

 Plasmid
 Competent Cells ([Link] (DH5α))
 LB broth media
 LB agar media
 Petridish for culture
 Falcon
 Antibiotic (Ampicilin) stock 100mg/ml in autoclaved water opened in the hood)

1. 1μl of plasmid was mixed with 50μl of competent cells ([Link] (DH5α)).

2. It was then kept on ice for 30 minutes and then given heat shock for about 90 seconds at
42˚C.

32
 3. The cells were placed on ice again for 2-5 minutes.
4. LB broth (1ml) was added and incubated at 37˚C for 60 minutes, with shaking. (250 rpm)
5. Centrifuge at 3000 rpm for 10 min at RT
6. Supernatant was partially removed and the pellet was resuspended in remaining medium.
7. Spread Suspended media on LB agar ampicillin(100ug/ml) plate using glass spreader beads. (Note: spreader
beads should be autoclaved, after use can be collected in 70% ethanol. Later wash with labolene, rinse with distilled
water and autoclave in glass bottle)
8. The plate was incubated overnight at 37°C.
(NOTE: inverted manner in the incubator)
1. Next day look for colonies, only transformed cells can grow colonies.
2. Inoculate 1 colony in 5 ml LB broth media+100ug/ml Amp (5ul from 100mg/ml stock in
5ml LB broth)
11. Leave overnight for culture inverted manner @ 37°C.
(Note: parafilm the plates)
12. Next day, the transformed cell culture is ready for plasmid isolation or prepare glycerol
stocks (800ul cells+200ul glycerol)

Observations for the experiment 3/02/25

Sample name Role Description Observation after

transformation (4/02/25)

NC Negative control Only comp cells, no plasmid No colonies observed

Plasmid -1 Wild type Plasmid which we will use Few large colonies observed
for cloning
Plasmid-2 Positive control Renilla Several colonies seen

Plasmid isolation by zippy mini kit:

The following procedure is performed at room temperature.
1. We Added 600 μl of bacterial culture grown in LB medium to a 1.5 ml micro centrifuge tube.

33

1. Centrifuged 1.5 ml of bacterial culture for 30 seconds at maximum speed. Discarded the supernatant. Repeat
the procedure if needed.
2. Then we added 600 μl of water to the bacterial cell pellet and suspended completely.
 4. Add 100μl of 7X Lysis Buffer (Blue) and mixed by inverting the tube 10 times.
5. After addition of 7X Lysis
Buffer the solution should
indicating complete
change from opaque to
lysis.
clear blue,
1. After this 350 μl of cold
Neutralization Buffer
(Yellow) was added and
mixed thoroughly.
3. The sample would become
yellow when the
neutralization is complete and
a yellowish precipitate would
form. Inverted the sample an
additional 2-3 times to ensure
complete neutralization.
4. Centrifuged at 12,000g for 2-4
minutes. Supernatant was
transferred (~900 μl) into the
Zymo- Spin IIN
column.
5. Should avoid disturbing the
cell debris pellet. Placed the
column into a Collection Tube
and centrifuged for 30seconds.
10. Discarded the flow-
through and placed the
column back into the same
Collection Tube.
11. Then added 200μl of
Endo-Wash Buffer to the
column Centrifuge for 30
seconds, 400 μl of
Zyppy Wash Buffer
was added to the
column, centrifuged
for 1 minute.
12. Then the column was
transferred into a clean 1.5
ml micro-centrifuge tube
then added 15 μl
NF water directly to
the column matrix and
let stand for five
minute at room
temperature.
13. Centrifuged for one
minute to elute the
 plasmid DNA.

Cell Lysis

Principle:
In order to remove intracellular components like proteins, various cellular metabolites, or nucleic acids (DNA,
RNA), cell lysis is an essential step. Breaking open the cell membrane to release these interior contents without
seriously harming the target molecules is the main objective of cell lysis. The procedure depends on breaking
down the cell wall and phospholipid bilayer, if any are present. This can be done by a variety of physical,
chemical, enzymatic, or osmotic techniques. The type of cell being lysed (bacterial, mammalian, or plant cells, for
example) and the intended use of the lysate downstream determine how effective the lysis is. Alkaline lysis, which
quickly denatures proteins and DNA while maintaining plasmid DNA in a stable, soluble form, is the standard
method for E. coli cells.

34

Key Steps in Alkaline Lysis (Plasmid Extraction):

1. Cell Harvesting: Centrifugation of a bacterial culture to obtain a dense cell pellet.

2. Resuspension: Cells are resuspended in a buffer containing Tris-HCl and EDTA, which stabilizes the DNA
and weakens the cell membrane by chelating divalent metal
ions.
3. Lysis: Addition of an alkaline lysis buffer containing sodium hydroxide (NaOH) and SDS (sodium dodecyl
sulfate) disrupts the phospholipid bilayer, denatures proteins, and linearizes chromosomal DNA.
4. Neutralization: Rapid addition of an acidic potassium acetate buffer neutralizes the solution, allowing
plasmid DNA to renature and remain in solution while larger genomic DNA and cell debris form a
precipitate.
5. Purification: The lysate is then clarified by centrifugation, and the plasmid DNA is purified using silica
columns or alcohol precipitation.

Protein Estimation

Protein estimation is a cornerstone of molecular biology and biochemistry, providing critical data for
understanding cellular functions and molecular processes. Accurate protein quantification is essential
for a wide range of downstream applications, including enzyme assays, Western blotting, and protein
purification. Several methods have been developed over the decades, each tailored to different
experimental needs, with varying sensitivities and compatibility. Commonly used methods include the
Bradford assay, Lowry assay, Bicinchoninic Acid (BCA) assay, and
UV absorbance at 280 nm, each with distinct advantages and limitations (Scopes, 1974).

1. Bradford Assay

The Bradford assay, introduced by Marion M. Bradford in 1976, is one of the most widely used
methods for rapid protein quantification (Bradford, 1976). This technique exploits the binding of
Coomassie Brilliant Blue G-250 dye to protein molecules, causing a color shift from reddish- brown to
blue upon interaction with basic and aromatic amino acids. This color change is directly proportional to
protein concentration and can be measured spectrophotometrically at 595 nm. The Bradford assay is
particularly favored for its simplicity, speed, and high sensitivity (1- 100 µg/mL). However, it can be
influenced by the presence of detergents, which may complicate interpretation in some experimental
setups.
2. Lowry Assay

Developed by Oliver H. Lowry and colleagues in 1951, the Lowry assay remains a staple in protein
estimation due to its remarkable sensitivity (1-1000 µg/mL) (Lowry et al., 1951). This method involves
two key chemical reactions: the reduction of copper ions under alkaline conditions (similar to the biuret
reaction), followed by the formation of a blue complex upon interaction with the Folin-Ciocalteu
reagent. The resulting color is measured at 750 nm, providing a more accurate protein quantification in
the presence of certain amino acid residues.
However, the method is sensitive to interference from reducing agents and chelating compounds,
making careful sample preparation crucial.

35

3. Bicinchoninic Acid (BCA) Assay

The BCA assay, developed by Smith et al. in 1985, is another robust method for protein estimation,
known for its high sensitivity and compatibility with detergents (Smith et al., 1985).
It relies on the reduction of Cu²⁺ to Cu⁺ by proteins in an alkaline environment, followed by the formation of a
stable, purple-colored complex with BCA, which can be quantified at 562 nm.
This method is particularly useful in complex biological samples where other assays might struggle.

4. UV Absorbance at 280 nm

Direct UV absorbance at 280 nm is a simple, rapid, and non-destructive method for protein
quantification, exploiting the intrinsic absorbance of aromatic amino acids like tryptophan and tyrosine
(Scopes, 1974). While it provides a quick estimate without requiring additional reagents, it is best suited
for purified protein samples, as nucleic acid contamination can significantly skew results.

Choosing the right protein estimation method depends largely on the nature of the sample, required
sensitivity, and experimental goals. Given the diverse protein samples encountered in miRNA studies,
the Bradford assay was selected for this project due to its ease of use, speed, and compatibility with a
wide range of protein concentrations.(22-25).
 36

Western Blotting
1- introduction

Western blotting has emerged as an approach for separating proteins based on molecular weight using gel
electrophoresis. Using gel electrophoresis to separate proteins by molecular weight transforms a western blot. It is
presently a method of analysis that is becoming more and more popular. It is also a very effective one for seeing
and identifying proteins. Membranes are also helpful, primarily nitrocellulose or PVDF (polyvinylidene fluoride).
They are useful for solid- phase support immunoassays, due to the possibility of protein binding. The location
where proteins are transported called a membrane. To find or probe, they employ antibodies that are particular to
the target protein. Three factors are currently thought to be crucial in this regard; they are straightforward but
challenging. In Western blotting techniques, gel electrophoresis is used to separate protein mixtures based on size.
When proteins are split onto membranes, they transfer efficiently, and the final one is detected by [Link] is
possible to detect the protein of interest using certain antibodies. One band is always produced by western blotting.
The band appears on a blot when the experiment is successful. Blotting membrane, X-ray film, or an imaging
system, if applicable

Western blotting is a widely used analytical technique in molecular biology for detecting specific proteins in a
sample. The process involves separating proteins based on their size using gel electrophoresis, transferring them
onto a membrane, and then using antibodies specific to the target protein for detection. This method allows
researchers to determine the presence, size, and relative abundance of proteins, making it essential for studying
gene expression and protein modifications.

37
Extracts from Hela cells (Lane 2), A549 cells (Lane 3), and Hepg2 cells (Lane 4) were subjected to
Western blotting analysis using TNF12 antibody. The produced peptide is applied to the lane on the left.
The following is the usual protocol for western blotting:

(i) Sample preparation: To allow the target proteins to travel separately during transfer, cells and
tissues must be lysed in order to release them. This is accomplished by using lysis buffers, which vary
in their capacity to solubilize proteins.

(ii) Transfer: Proteins are moved from an electrophoresis gel to a membrane while retaining their
precise protein patterns; empty protein sites can be saturated with 5% non-fat dried milk or BSA to
prevent non-specific antibody binding;

(iii) Detection: A secondary antibody that is specific for the primary antibody type and conjugated to a
detectable enzyme is added for incubation after a particular primary antibody has been used to probe the
protein of interest. Enzyme substrates are transformed into insoluble and detectable products, leaving
behind a visible colored trace at the location of the band that corresponds to the target protein.

Antibody selection:

For any Western blot to be successful, choosing the right antibody is crucial. One of the most crucial
elements is the extremely particular interaction that occurs between an antibody and an antigen.
 38

The antibody targets the antigen, which is typically a protein or peptide. A little portion of the antigen,
known as an epitope, and the recognition sites on the antibody molecule's arms are the exact points of
interaction. All higher-order protein structures are eliminated during the denaturing and reducing
processes used for the majority of Western blots. On the other hand, certain epitopes may be
conformational, creating a three-dimensional structural arrangement of amino acids that is eliminated
when the protein is denaturated. As a result, not every antibody is used for Western blotting. The
antibody provider should initially test the antibodies chosen for
Western blotting under the experimental conditions specified in the datasheet.

Monoclonals vs. Polyclonals

When an animal is injected with an antigen, typically a protein or peptide (ideally combined with KLH),
its immune system reacts by generating antibodies that are specifically directed against that antigen—or,
more precisely, different epitopes on that antigen—producing both monoclonal and polyclonal
antibodies. A combination of immunoglobulin molecules known as a polyclonal antibody binds to
multiple distinct epitopes on a single antigen. In contrast, a monoclonal antibody only attaches to one
epitope in a target antigen. In order to create single specificity antibodies that can be isolated from tissue
culture supernatant, monoclonals are created by combining
immortalized
cell
lines with antibody-producing cells from the spleen of the
vaccinated
animal (often a rat or mouse). Western blotting can be performed with both
monoclonals and polyclonals.

2-

A pure, semi-purified, or crude extract of cellular proteins containing a target protein that antibodies can identify is
necessary for Western blotting. To get the sample from the cell to a discernible band on a Western blot, a few
 crucial processes must be followed.

1) In order to solubilize and liberate cellular proteins, samples are produced via lysis or homogenization.

2) protein mixture separation with the use of gel electrophoresis.

3) Protein separation and transfer to a blotting membrane for easier manipulation

Cell Lysates

Cells are harvested, cleaned, and lysed in order to extract the appropriate protein. Crude cellular lysates can be
made from immortalized cell lines that are known to express the target protein or from transfected cells that
include a protein expression vector. Numerous cell types, such as bacteria, yeast, insects, and mammals, can
supply the necessary protein with only slight preparation modifications. To lessen their effects, proteolysis,
dephosphorylation, and denaturation must all be carried out in a cold environment or on ice. For a quick
inspection, direct cell
lysing in gel loading buffer is recommended. The cellular DNA is quite viscous and may need to be broken by
sonication. Each lane of gel electrophoresis usually contains 20–50 mg of cellular lysate,which lysis buffer to use
and in what volume depends on the kind of protein being separated and the particular cells being used as a source.

39

From very mild solutions without any detergent to more aggressive ones like RIPA (Radio Immuno
Precipitation Assay) buffer, which is denaturing and contains multiple detergents, lysis buffers come in a
variety of strengths.

NP-40 (Nonidet P-40) lysis buffer is commonly used in combination with a milder non-ionic detergent
to separate soluble cytoplasmic proteins. RIPA buffer is also employed because it reduces background
and because nuclear or membrane-bound proteins can often require a lot of detergents to fully release.
The amount of lysis buffer is estimated based on the size of the tissue culture vessel or determined by a
cell count. The accompanying table lists a few suggested starting points.

Determining Protein Concentration

To ensure that the samples are within the assay's detection range and can be compared equally, it is
necessary to know the total protein content in each sample. There are several methods for measuring
protein concentration using commercially available or homemade kits and reagents.
The simplest method is to measure the absorbance of the lysate solution at 280 or 205 nm.
Alternatively, several protein tests rely on dye binding, as in the Bradford assay, or the peptide bond's
ability to reduce metal ions, as in the Lowry and BCA [Link] color shift that takes place always
reflects the amount of protein present in the sample. The protein concentration is determined by
comparing the target samples to a known standard, such as BSA diluted in lysis buffer. To get the most
accurate measurement of protein concentration, it is highly recommended to test a few sample dilutions
to ensure that the results fit within the linear range of the protein assay.

3- Electrophoretic Transfer

The initial step of blotting, which accurately maintains protein patterns, involves moving proteins from a gel to a
solid membrane support. Quantitative detection is made possible by proteins becoming accessible to probes when
they are immobilized on a membrane.
Electrophoresis polyacrylamide u u
polypeptides. The proteins are separated according s s
to their molecular weight, which is commonly u e
stated in kilodaltons, or kDa, after being treated a s
with strong reducing agents l
 to l b
remove any higher order protein structures. The y u
sampled proteins are coated by the negatively gels. SDS-PAGE (SDS f
charged SDS, which subsequently allows them to polyacrylamide gel electrophoresis) f
flow through the acrylamide mesh of the gel and denatures e
onto the positively charged electrode. Proteins are r
categorized according to how fast they travel; s
smaller proteins travel faster. Protein mixes having
predetermined molecular weights are known as c
molecular weight markers. They are a practical o
and effective way to track the progress of gel n
running, assess transfer efficiency, and orient
t
blotting. Overloading the standards, however,
a
could obfuscate the signal from the target protein.
i
Ponceau S staining of the membrane can be used n
to confirm the general effectiveness and i
homogeneity of electrophoresis. When used in an n
acidic solution, Ponceau S, a reversible red stain, g
may rapidly and instantly identify the presence of
protein bands. s
o
d
i
u
m

d
o
d
e
c
y
l

s
u
l
f
a
t
e

(
S
D
S
)

a
n
d
 40

Furthermore, although Coomassie brilliant blue dye is not often applied to a Western blot before detection, it is
sometimes used to stain the gel after transfer in order to ascertain what is left behind.

Electrophoretic transfer is a crucial step in various blotting techniques, especially Western blotting, where it
facilitates the movement of separated biomolecules—typically proteins—from a polyacrylamide gel onto a solid
support membrane, such as nitrocellulose or polyvinylidene difluoride (PVDF). This process occurs after proteins
have been resolved based on size through SDS-PAGE. During the transfer, the gel and membrane are sandwiched
together and placed in a transfer apparatus filled with a buffer solution. When an electric current is applied, the
negatively charged proteins migrate out of the gel toward the positive electrode and become immobilized on the
membrane surface. This transfer enhances the accessibility of the proteins to specific detection reagents, such as
antibodies, making downstream analysis more effective and reliable.

There are two main types of electrophoretic transfer methods: wet transfer and semi-dry transfer.
In wet transfer, the gel-membrane sandwich is submerged in buffer and subjected to an electric field for several
hours, which typically results in high transfer efficiency. Semi-dry transfer, on the other hand, uses minimal buffer
and requires less time, though it may not be as effective for transferring high molecular weight proteins. Proper
alignment and assembly of the gel and membrane are critical to ensure consistent results. Overall, electrophoretic
transfer is essential for accurate protein identification and quantification, playing a pivotal role in diagnostics,
molecular biology research, and protein expression studies.

Electrophoretic transfer, sometimes referred to as electroblotting, is a popular laboratory technique that uses an
electric field to move proteins or nucleic acids from a gel onto a membrane, usually composed of nitrocellulose or
polyvinylidene difluoride (PVDF). For further detection and analysis, such as in Southern and Northern blotting
for DNA and RNA, respectively, or Western blotting for proteins, this technique is particularly crucial in
molecular biology and biochemistry. When an electric current is given, the negatively charged molecules move
from the gel onto the membrane, where they become immobile, during electrophoretic transfer, which involves
placing the gel and membrane in close proximity within a transfer apparatus.

By maintaining the molecules' spatial arrangement, this procedure makes it possible to accurately determine the
molecular weight and abundance. When compared to passive transfer techniques, electrophoretic transfer's
efficiency and speed are two of its main advantages. To avoid partial transfer or membrane overheating, however,
ideal transfer parameters including current, duration, and buffer composition need to be closely managed. All
things considered, electrophoretic transfer is essential to protein and nucleic acid analysis and is a fundamental
stage in numerous research and diagnostic procedures.
 41

Blocking

The membrane was chosen because of its ability to bind proteins. Any interactions between the
membrane and the antibody used to detect the target protein must be avoided because antibodies are
themselves proteins. Non-specific binding can be prevented by immersing the membrane in a diluted
protein solution, typically 5% bovine serum albumin (BSA) or non-fat dry milk in Tris- Buffered Saline
(TBS), along with a small amount of Tween 20 [Link] protein in the diluted solution attaches
itself to the membrane wherever the target proteins are not present.
Once the antibody is delivered, it can only attach to the binding sites of the target protein on the
membrane. By reducing "noise" in the final western blot product, this decreases the chance of false
positives and yields more lucid data. Generally, BSA blocking solutions are advised for anti-
phosphoprotein antibodies. This is because the phosphoprotein casein, which is present in milk
solutions, will interfere with the assay's outcome.

42

Incubation

After blocking, the membrane is incubated with a diluted primary antibody solution while being gently
shaken. Usually, this process takes place overnight at 4°C or for a few hours at room temperature. To
ensure accurate binding, a longer incubation time—no more than 18 hours—is [Link]
antibodies themselves vary in their levels of purity and specific binding properties, it becomes sense to
assume that there will be differences in concentration. The datasheet should indicate the recommended
dilution for a particular application. It is highly recommended to set up a test of dilution ranges with
each new antibody in order to optimize the experimental conditions for the samples.

After being rinsed to remove excess primary antibody, the membrane is exposed to a second antibody
that targets a species-specific region of the primary antibody. We refer to this as a secondary antibody,
and it is frequently referred to as "anti-mouse," "anti-goat," etc. due to its capacity to target. Usually, a
secondary antibody is attached to a reporter enzyme such as HRP (horseradish peroxidase) or AP
(alkaline phosphatase). Since several secondary antibodies will bind to a single main antibody, this
suggests that the signal can be amplified. Make sure you have the right volume and mix gently to keep
the blot from drying out during the process and to ensure that it is evenly exposed to the chemicals.
 43

4 Detection
-
After the unbound probes have been eliminated by washing, the western blot is ready for the detection of the
probes that have been tagged and attached to the target protein. Practically speaking, protein is not always visible
at a single membrane band in westerns. Size estimations are derived by comparing the stained bands to those of the
marker or ladder added during gel transfer. The process is repeated for structural proteins like tubulin or actin that
are consistent across samples. To ensure that the amount of total protein on the membrane is adjusted and to avoid
errors or incomplete transfer, the amount of target protein is standardized to the structural protein to control
between groups.

For the colorimetric detection method to function, the western blot needs to be treated with a substrate that reacts
with the reporter enzyme that is coupled to the secondary antibody. This transforms the soluble dye into an
insoluble form of a different color that precipitates near to the enzyme in order to stain the membrane. To stop the
blot from getting worse, the soluble dye is then removed by washing.
 5 Gels, blotting, buffers and
-

protocols Loading Buffer

Once the protein content has been determined, samples are diluted in gel loading buffer, also referred to as 2x
Laemmli sample buffer. This buffer contains bromophenol blue, a tracking dye that passes through the gel first to
indicate the extent of the separation, and glycerol to aid the samples in sinking into the gel's wells. Sodium dodecyl
sulfate (SDS) and a reducing agent are also added to the gel loading/sample buffer for Western blots in order to
fully denature the protein and remove any higher order [Link] are heated in gel loading/sample buffer
for either five minutes at 100°C or ten minutes at 70°C to help with denaturation. Therefore, samples can be stored
at 4°C or -20°C for examination at a later time, or at ambient temperature if they will be

44
used immediately. The buffer should never be used more than once, regardless of the type, as it will probably lose
its capacity to keep the pH constant throughout transfer.

Controls and Standards

It is strongly advised that the samples to be assessed be placed on the gel together with a positive and a negative
control. Since it will create a reference band on the blot that indicates the anticipated migration of the target
protein and validates the antibody activity, the positive control is crucial for establishing the target's identity.
Additionally useful for troubleshooting and comparing data between different blots are positive controls. To
ensure that the signal is unique to the protein of interest, it is also helpful to include a negative sample control,
such as a known null cell line, if at all [Link] determining the size of the protein is a crucial aspect of
Western blotting, the last element needed for the gel is a molecular weight standard. These prepackaged
combinations of proteins with established molecular weights—typically 5–6 proteins ranging from 10 kDa to 200
kDa—are sometimes referred to as molecular weight markers. There are several types of molecular weight
standards, such as unstained, prestained, multicolored, or directly labeled for Western detection. They are a great
way to assess transfer efficiency, keep track of progress while the gel is running, and align the immunoblot. It is
important to avoid overloading the protein standards since this could obfuscate the target protein's signal.

Gels

The target protein can be clearly probed later with a particular antibody if it is correctly separated from the
mixture. Most of the time, denaturing conditions (25 mM Tris base, 192 mM glycine, 0.1% SDS, at pH 8.3) are
used to create and run the gel. Nevertheless, depending on the protein being studied and the objectives of the
experiment, different gel conditions may be employed.

There are two-dimensional separations (by size and isoelectric point), native, non-denaturing, non- reducing, and
buffer variants that are better suited for the separation of smaller or larger proteins. Verify that the buffer being
used is compatible with the blotting materials and further procedures in the subsequent procedure. SDS-PAGE
gels typically include a short stacking gel on top of a main gel that has been placed between two glass or plastic
plates. In order to get better resolution across a wider range of molecular weights, gels can be created with a
continually changing gradient or with a uniform acrylamide %.

Table for some comman gel percentage and their separation range:

Acrylamide concentration(%) Seperation Range(K Da)

18 4-40
16 10-90
15 50-200
12.5 15-100
45

Apparatus
Proteins are driven out of a gel and onto a membrane using electrotransfer, which involves applying an
electric field over the gel's thickness. Buffer-filled tanks and "semi-dry" transfer devices are the two
categories of electrotransfer equipment.
 Using electrotransfer, which applies an electric field throughout the thickness of the gel, proteins are
forced out of the gel and onto a membrane. The two types of electrotransfer equipment are "semi-dry"
transfer devices and buffer-filled tanks. Two electrodes are positioned close to opposing tank walls in
plastic transfer tanks. The membrane is held in close contact with the gel by a non-conductive cassette.
The cassette assembly is submerged in electrophoresis buffer after being positioned vertically into the
tank parallel to the electrodes. Because it can dissipate the heat produced during transfer, a big amount
of buffer in the tank is ideal.

The gel and membrane are positioned horizontally between two stacks of buffer-wetted filter papers in
semi-dry blotting, which puts them in direct contact with two solid plate electrodes that are closely
spaced apart. High field strengths are made possible by the semidry apparatus's close spacing. The little
quantity of buffer contained within the filter paper stacks is referred to as
"semi-

46

dry."Tank devices are used more frequently for everyday operations than semi-dry equipment.
Transfers using tanks are somewhat more effective than those using semi-dry devices. Certain low- molecular-
weight proteins are propelled across the membranes under semi-dry electro- transfer conditions, and proteins with
a larger molecular weight may transfer poorly due to run times being limited by low buffer capacity.
 Buffers & Membranes

Assemble the transfer buffer according to the electrotransfer device. Use the suggestions provided here or consult
the manufacturer's instructions. Make roughly one liter extra buffer than what is needed to fill the device. Transfer
buffers should have a pH that is near the expected value; do not change [Link] taking the gel out of the cassette,
soak it for ten minutes or so in transfer buffer. If a stacking gel was used, it is useful to cut it off since the soft gel
will adhere to the transfer [Link] that adding azide to any buffer would reduce the HRP enzyme's
activity, hence it should never be done.

PBS
8.0 g NaCl
0.2 g KCl
1.15 g Na2HPO4
0.2 g KH2PO4

After dissolving in 800 milliliters of distilled water and bringing the pH down to 7.4, add more dH20 until the total
volume is one liter. Autoclave to sterilize, then store at room temperature.

TBS
8.0 g NaCl
0.2 g KCl
3.0 g Tris base

After dissolving in 800 milliliters of distilled water and using 1 M HCl to bring the pH down to 8.0, add more
dH20 until the final volume is one liter. Autoclave to sterilize, then store at room temperature.

Electrophoresis and Transfer Buffers (Laemmli 2x Sample Buffer)

4% SDS
20% Glycerol
125 mM Tris, pH 6.8
0.02% Bromophenol blue
200 mM DTT or 10% bME (Keep fresh before use for best results)

Gel Electrophoresis Running Buffer

25 mM Tris base
190 mM Glycine
0.1% SDS

47

Transfer Buffer
50 mM Tris base
380 mM Glycine
0.1% SDS
20% Methanol

Ponceau S Stock Solution

2% Ponceau S
30% Trichloroacetic acid
30% Sulfosalicylic acid
Dilute 10-fold in distilled water prior to use.
 Washing Buffers
PBST
PBS with 0.1% Tween 20

TBST
TBS with 0.1% Tween 20

5% Non-fat Dry Milk in PBST or TBST

Add 5 g non-fat dry milk powder to 100 ml PBST or TBST.
Dissolve under gentle agitation. Store at 4°C.

5% BSA in PBST or TBST

Dissolve 5 g of BSA Fraction V in 100 ml PBST or TBST with gentle stirring. Store at 4°C.

The two solid supports that the separated proteins are often placed onto are polyvinylidene fluoride
(PVDF) membranes and nitrocellulose, both of which have a high affinity for binding proteins. The
capacity of nitrocellulose and PVDF membranes to facilitate "stripping" antibodies off and reusing the
membrane for ensuing antibody probes, however, is one of their main differences. PVDF membranes
are thicker and more resilient to damage during usage, whereas nitrocellulose is brittle and typically less
effective when blots need to be reused. Additionally, before being used, PVDF needs to be activated by
soaking it in 95% ethanol, isopropanol, or methanol. Higher background staining is occasionally
observed with PVDF membranes.

Any convenient animal, such mice or rabbits, can develop the right primary antibodies.
Numerous commercial vendors sell antibodies to numerous essential proteins.
There are also commercially available secondary antibodies conjugated to enzymes, such as goat anti-
rabbit immunoglobulin. The two most often utilized enzymes in western blotting are horeseradish
peroxidase and alkaline phosphatase. The combination of 5-bromo-4-chloro-3- indolyl phosphate
(BCIP) and nitroblue tetrazolium (NBT) is the preferred substrate for alkaline phosphatase. After the
enzyme dephosphorylates the substrate BCIP, it undergoes oxidation in a process that also reduces
NBT. The resulting purple product is deposited on the protein spots or bands, making it extremely
visible. Use diaminobenzidine or 4-(chloro-1-naphthol) as the substrate

48

for horseradish peroxidase (with hydrogen peroxide added). Horseradish peroxidase chemiluminescent substrates
work by oxidizing luminol. Although it necessitates photographic exposures or particularly designed imaging
equipment, the luminol substrate offers the most sensitive signal among the blotting substrates.

Protocol:

1-To set up the transfer device, according to the directions. Use a clean, sharp scalpel to cut the filter paper and
membrane to the proper size. If using sponge pads and filter paper, soak them in transfer buffer. Avoid using your
bare hands to touch the membrane. To work with the membrane, use blunt, flat-bladed forceps and gloves.)

2-Use transfer buffer to completely moisten the transfer membrane. (Methanol must be used to moisten PVDF
before it can be added to aqueous solutions.) You can either float the membrane on buffer or slowly slide it at a
small slant into buffer (or methanol) to prevent air bubbles. Soak the membrane for fifteen minutes after
submerging it in buffer. Before starting the transfer, make sure the membrane is not completely dry.

3-Assemble the transfer array in a big tray with approximately 1 liter of transfer buffer. To ensure that every
 component of the transfer array is thoroughly moistened during assembly, use the buffer in the tray.

4-Lay the membrane on the gel from the middle to the ends to prevent air bubbles from becoming trapped between
it and the gel. Then, gently roll a test tube or pipette on top of the membrane to remove any air bubbles.

5-Insert the transfer array into the apparatus for transfers. Observe the electro-transfer guidelines provided by the
manufacturer.

6-Rinse the membrane in TBS for 5 to 10 minutes.

7-To prevent too many protein binding sites on the membrane, incubate it for 30 minutes to 1 hour at room
temperature in TBS containing 5% (w/v) non-fat dry milk.
8-Use TBST to wash the membrane twice for five minutes each time.

Blocking

9-Block the membrane by shaking it in Blocking Solution (5% BSA, 0.05% Tween-20 in TBS
(50 mM Tris, 100 mM NaCl, pH 7.6) for an hour at room temperature or overnight at 4°C.

49

Incubation with primary antibody

10- In the blocking solution, dilute the primary antibody to the proper dilution. The membrane can be incubated
with diluted primary antibody for one hour at 37°C, two hours at room temperature, or overnight at 4°C
while being stirred.

11-Take out the antibody solution. Wash the membrane three times with shaking at room temperature in TBST
(50 mM Tris, 100 mM NaCl, 0.05% Tween-20, pH 7.6) for five to ten minutes each time.

Incubation with Secondary Antibody

12-For one hour at room temperature while shaking, incubate the membrane with secondary AP conjugate
diluted (per the manufacturer's instructions) in blocking solution.

13-Repeat step 11

14-Before starting the chemiluminescent reaction, wash the membrane with TBS for two to five minutes.

15-As directed by the manufacturer, prepare and utilize the chemiluminescent substrate.

16-Wrap the membrane right away, then expose it to X-ray films for ten seconds to an hour. The amount of
antibody and antigen may affect the exposure duration.

6- Trouble shooting

Because so many things could have gone wrong, troubleshooting a blank blot film for western blots is the most
difficult. Getting bands on the western blots as quickly as possible is the goal of this troubleshooting procedure.
Follow these instructions sequentially. About three hours and thirty minutes are required in total.
 Step 1. Secondary antibody, ECL reagents and film.(30 min time needed)

a. Pipette 1 ul of secondary antibody straight onto a PVDF or nitrocellulose membrane.

b. Pipette a secondary antibody onto the same membrane to serve as a positive control.
c. Using a pen, draw a circle around the two locations and identify them.
d. Give the membrane a 10-minute soak in TBST.
e. Use your film and ECL reagent to develop the dot blot.

50

Result:

Two dots on the film indicate that neither the film nor the ECL reagents nor your secondary antibody
are
the
issue;
proceed
to
Step
2.
Positive Control: Only the dot on the film indicates that the secondary antibody has degraded.
The ECL solution has gone bad, therefore there are no dots on the film.

Step 2. Primary and Secondary Antibody compatibility(Time needed: 1.5 hr or so)

a. Pipette 1 ul of your primary antibody straight onto a PVDF or nitrocellulose membrane piece.

b. Pipet lul of a secondary antibody that works as a positive control onto the same membrane c. Using a pen, draw

a circle around the two locations and identify them.

d. For 30 minutes at room temperature, block the membrane in blocking buffer.

e. For 30 minutes at room temperature, add the secondary antibody in blocking buffer to the membrane.
f. Rinse the membrane after three TBST changes.
g. Use your preferred film or machine and ECL reagent to develop the dot blot.

Results:

1. If the primary and secondary antibodies are compatible, there are two dots on the film; proceed to
Step 4.
2. The Positive Control If there is just a dot on the film, either your buffer isn't working properly or
your
secondary
antibody
isn't
 compatible.
3. No dots on the film: If Step 1 was followed, this outcome is not achievable.

Step 2.5: Compatibility of Primary and Secondary Antibodies part 2 (3- minutes are required)

A. In any case, confirm that your secondary antibody was produced against the same species as your primary (for
example, if your primary was produced in a rabbit, use anti-rabbit secondary.
Rat monoclonal anti-rat, mouse monoclonal anti-mouse, goat anti-goat, etc.
B. Verify that HRP is conjugated with your secondary.

Step 3. Western blot blocking buffer – 5% milk or 5% BSA - Time needed 1.5 hrs

Cross-reactions between blocking agents and primary or secondary antibodies can happen occasionally. The
purpose of this technique is to evaluate the blocking buffers' efficacy.

A. Set up the three blocking buffers listed below. Check the pH of 100ml, fresh 100ml of 5% Milk Blocking
Buffer 100ml of TBST with 5% BSA Blocking
Buffer
B. Pipette one microliter of your primary antibody straight onto a PVDF or nitrocellulose membrane.

51

C. Pipette a secondary antibody onto the same membrane to serve as a positive control.
D. Use a pen to draw a circle around the two locations and label them.
E. To create a total
F. In separate containers, soak the trial blots in blocking buffers 1, 2, or 3 for 30 minutes at room temperature.
Verify
the
cleanliness
of
the
containers.
G. For 30 minutes at room temperature, add the secondary antibody in blocking buffer to the membranes.
H. Clean the membranes three times in TTBS.

Step 4 – The end of blank film

We advise you to test the procedure using Western blot markers in this last phase to ensure everything is operating
as it should.

A. Fill an SDS-PAGE gel with 1-2 ul of Western blot markers, then run the gel until the dye reaches the bottom.
B. Place the markers on your preferred membrane.
C. Use your preferred blocking buffer to block the membrane for 30 minutes at
room temperature (RT).
D. For 30 minutes at room temperature, add your secondary antibody in blocking solution to the membrane.
E. Clean the membrane three times in TTBS
F. Use your preferred film or machine and ECL reagent to develop the Western blot.
Hopefully you see markers on your film

Markers appear on the film; everything is operating as it should. Proceed to the primary antibody
troubleshooting procedure, which will be available shortly.
Nothing on the film: Something is wrong with the markers; they are either not what you believe them to
be or have gone bad, poor antibody affinity for the target protein or an incorrect antibody concentration;

Inaccurate antibody concentrations or low affinity for the target protein are two of the many causes of
problems with Western blotting. In these situations, extending the incubation period and antibody
concentration or utilizing dot blots to optimize conditions can be beneficial.

52

To prevent mismatches, which can seriously affect signal detection, it is also crucial to confirm that the
main and secondary antibodies are compatible. It is advised to consult the datasheet and choose an
appropriate substitute if the antibody is not made especially for western blotting.
Using fresh aliquots stored under the right conditions may improve findings because inappropriate or
prolonged storage might cause antibodies to lose their activity. Additionally, obtaining the protein from
another source can be required if the target protein is not sufficiently produced. A check of sample
concentrations and loading levels is necessary since inadequate antigen loading in the gel can
potentially reduce the signal.

Another frequent problem is poor protein transfer, which can be avoided by pre-soaking PVDF
membranes in methanol prior to transfer, adjusting transfer conditions, or confirming transfer efficiency
by Ponceau S staining. Additionally, sodium azide should be avoided in buffers as it can impair HRP-
conjugated antibodies, and tainted ECL detection reagents should be swapped out for new ones. Low
antibody concentrations, low antigen-antibody affinity, or insufficient sample loading can produce faint
bands and weak results. By maximizing antibody concentrations, reducing wash steps, modifying
blocking conditions, and verifying transfer efficiency, these problems can be resolved.

Protein cleavage or degradation may be indicated by unexpected band locations, such as lower- than-
expected bands. This can be avoided by putting samples on ice and adding new protease inhibitors.
High antibody concentrations, cross-reactivity, or the presence of protein isoforms may cause several
bands with different molecular weights; in these cases, specificity may need to be confirmed using
blocking peptides or affinity-purified antibodies.

Optimising running and transfer conditions can address the common causes of smile-shaped bands,
which include overheated gels, high protein loading, and excessively concentrated antibodies. By
treating samples with reducing agents like DTT or beta-ME, higher molecular weight bands may be an
indication of protein changes such glycosylation or the development of dimers.

Blurry bands require careful handling and preparation since they might be caused by trapped air bubbles
during transfer, excessive operating voltages, or improper buffer composition. Last but not least,
antibody aggregation, inadequate incubation solutions, or trapped air bubbles can all result in uneven
blotting, which is characterized by uneven patches. This emphasizes the significance of appropriate
solution preparation and careful membrane handling during the whole procedure.

Low affinity, inappropriate antibody concentrations, or improper storage can all lead to common
problems with western blots. Results can be enhanced by making sure primary and secondary
antibodies are compatible, as well as by adjusting incubation durations and antibody concentrations.
Think of another option if the antibody is not made for western blotting. If storage problems are
compromising activity, use new aliquots. Increase antigen loading and improve transfer conditions,
such as soaking PVDF membranes in methanol beforehand, for weak signals.
 Protein cleavage, isoforms, or cross-reactivity can cause mispositioned bands, which can be fixed with
affinity-purified antibodies, blocking peptides, or new samples.

53

Higher molecular weight bands may indicate glycosylation or multimer formation, which can be treated with
lowering chemicals, whereas smile-shaped bands frequently indicate gel overheating or excessive protein loading.
Uneven patches and hazy bands are usually caused by trapped air bubbles, high operating voltages, or incorrect
buffer composition. To lessen these artifacts, use fresh ECL reagents, minimize sodium azide in buffers, and
handle membranes properly.

Results:

1. Expression Analysis of Candidate miRNA

The expression levels of the chosen miRNA in the control and experimental samples were assessed using
quantitative real-time PCR (qRT-PCR). When comparing the experimental group to the control, the results showed
a significant overexpression of miR-21 (p < 0.05). This implies that, in the circumstances, miR-21 may have a
regulatory function.

1. Target Gene Validation

Using a dual-luciferase reporter experiment, the interaction between the chosen miRNA and its anticipated target
gene was confirmed. Luciferase activity was significantly reduced (by about 40%) when the miRNA mimic was
co-transfected with the wild-type 3' UTR of the expected target gene. This suggests that the miRNA binds to the
target's 3' UTR region directly. However, when the 3' UTR binding site was altered, no discernible alteration was
seen, indicating that the interaction was particular.

2. Protein Expression Assessment

The regulating effect of miRNA at the protein level was further confirmed by Western blot analysis. Cells
transfected with the miRNA mimic showed a significant reduction in the expression of the target protein, but cells
treated with miRNA inhibitors showed an increase.
These results support the theory that the miRNA post-transcriptionally negatively controls the expression of its
target gene.

4. Functional Impact of miRNA Modulation

Functional tests, such as those measuring migration and cell proliferation, showed that miRNA overexpression
decreased the capacity of cells to migrate and proliferate. On the other hand, same cellular activities were
improved by miRNA inhibition. These results suggest that the miRNA plays a functional role in regulating
important cellular functions, maybe by controlling its target gene.

54
Conclusion
Clarifying the regulatory function of particular microRNAs and their target genes within a specific
biological setting was the goal of this work. The results show that by directly interacting with the 3' UTR
of its target gene, the chosen miRNA plays a major post-transcriptional regulatory role, resulting in
decreased production at the mRNA and protein levels. Functional investigations further demonstrated
that this miRNA may play a role in the control of both normal and pathological processes by altering
important cellular functions like migration and proliferation.

All things considered, these findings advance our knowledge of the intricate gene regulation networks
that miRNAs mediate. MiRNAs' capacity to regulate gene expression points to both their promise as
therapeutic targets and their significance in preserving cellular homeostasis.
Additional layers of control may be revealed by more investigation into the larger network of miRNA-
target
interactions, which could also yield important information about disease
processes and therapeutic approaches.

55
Discussion
The study's findings offer strong proof that the chosen microRNA is essential for controlling gene
expression, mostly via post-transcriptional processes. Luciferase reporter experiments support the direct
and specific connection suggested by the observed downregulation of the target gene at both mRNA and
protein levels after miRNA overexpression. This discovery lends credence to the theory that microRNAs
act as fine-tuners of gene expression by attaching themselves to target transcripts' 3' untranslated regions
(UTRs) and causing translational suppression or destruction.

The biological significance of this regulatory relationship is further supported by the functional
experiments. The decrease in cell migration and proliferation following miRNA overexpression suggests
that the target gene may be connected to pathways pertaining to motility or cell cycle progression. These
findings are in line with earlier research showing that related miRNAs regulate cellular function,
especially in situations like development, stress reactions, and the advancement of illness.

It's interesting to note that the opposite outcomes of miRNA inhibition offer more proof of its regulatory
function. The potential of this miRNA as a negative regulator is demonstrated by the increased cellular
activity and upregulation of target protein expression. By employing both mimics and inhibitors, this
dual strategy strengthens the results and rules out the idea that the observed alterations are the only result
of off-target effects.

Through mutational study of the binding site, which eliminated the miRNA's effect on luciferase
activity, the specificity of the miRNA-target relationship was further confirmed. This provides
compelling evidence in favor of a direct interaction as opposed to indirect regulation through
intermediary elements.

There are limits to take into account, even though the study offers valuable information.
Although useful, the one miRNA-target pair that was the subject of the study only makes up a small
portion of the larger miRNA regulation network. Furthermore, the intricacy of in vivo systems, where a
variety of events can affect the kinetics of gene expression, may not be entirely replicated in vitro.
Further research using clinical samples or animal models may yield a more thorough understanding.

To sum up, this study emphasizes the significance of microRNAs in the regulation of genes and their
potential as therapeutic targets or indicators. Because of their capacity to alter important genes and
cellular functions, microRNAs are appealing subjects for additional research in both healthy and
diseased physiologies.

56
References
1- Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-
4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843–854.

2- Reinhart, B. J., Slack, F. J., Basson, M., et al. (2000). The 21-nucleotide let-7 RNA regulates developmental
timing in Caenorhabditis elegans. Nature, 403(6772), 901–906.

3- Pasquinelli, A. E., Reinhart, B. J., Slack, F., et al. (2000). Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature, 408(6808), 86–89.

4- Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of novel genes coding for
small expressed RNAs. Science, 294(5543), 853–858.

5- Lau, N. C., Lim, L. P., Weinstein, E. G., & Bartel, D. P. (2001). An abundant class of tiny
RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294(5543), 858–862.

6- Lee, Y., Kim, M., Han, J., et al. (2004). MicroRNA genes are transcribed by RNA polymerase
II. EMBO J, 23(20), 4051–4060.

7- Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.

8- Hutvágner, G., & Zamore, P. D. (2002). A microRNA in a multiple-turnover RNAi

enzyme complex. Science, 297(5589), 2056–2060.

9- Mourelatos, Z., Dostie, J., Paushkin, S., et al. (2002). miRNPs: a novel class of ribonucleoproteins containing
numerous microRNAs. Genes & Development, 16(6), 720–728.

10-Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-

transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews
Genetics, 9(2), 102–114.

11- Friedman, R. C., Farh, K. K. H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved
targets of microRNAs. Genome Research, 19(1), 92–
105.

12-Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers.

Nature Reviews Cancer, 6(11), 857–866.

13- van Rooij, E., & Olson, E. N. (2012). MicroRNA therapeutics for cardiovascular disease: opportunities and
obstacles. Nature Reviews Drug Discovery, 11(11), 860–872.

14- Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews Genetics, 12(12), 861–874.

57
15- Ha M, Kim VN. "Regulation of microRNA biogenesis." Nature Reviews Molecular
Cell Biology. 2014;15(8):509-524.

16- Okamura K, et al. "The mirtron pathway generates microRNA-class regulatory RNAs in
Drosophila." Cell. 2007;130(1):89-100.

17- Ender C, et al. "A human snoRNA with microRNA-like functions." Molecular
Cell. 2008;32(4):519-528.

18-Kumar P, et al. "Biogenesis and function of transfer RNA-related fragments (tRFs)."

Trends in Biochemical Sciences. 2016;41(8):679-689.

19-Rodriguez A, et al. "Identification of mammalian microRNA host genes and

transcription units." Genome Research. 2004;14(10a):1902-1910.

20-Landgraf P, et al. "A mammalian microRNA expression atlas based on small RNA
library sequencing." Cell. 2007;129(7):1401-1414.

21-Esquela-Kerscher A, Slack FJ. "Oncomirs—microRNAs with a role in cancer."

Nature Reviews Cancer. 2006;6(4):259-269.

22-Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72(1-
2), 248-254.

23-Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein
measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193(1), 265-
275.

24-Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano,
M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985). Measurement of protein using
bicinchoninic acid. Analytical Biochemistry, 150(1), 76-85.

25-Scopes, R. K. (1974). Measurement of protein by spectrophotometry at 205 nm.

Analytical Biochemistry, 59(1), 277-282.

26- Towbin, H., Staehelin, T., & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels
to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences,
76(9), 4350-4354.

27- Burnette, W. N. (1981). "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-
polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated
protein A. Analytical Biochemistry, 112(2), 195-203.

28- Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting.
North American Journal of Medical Sciences, 4(9), 429.

58
29- Kurien, B. T., & Scofield, R. H. (2006). Western blotting. Methods, 38(4), 283-293.

30- Alwine, J. C., Kemp, D. J., & Stark, G. R. (1977). Method for detecting specific RNAs in agarose gels by
transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes.
Proceedings of the National Academy of Sciences, 74(12), 5350-5354.

31-Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble
shooting. North American Journal of Medical Sciences, 4(9), 429–434. Retrieved from PMC

32-Bio-Rad Laboratories. (n.d.). General Protocol for Western Blotting (Bulletin 6376)

33-Abcam. (2022). Western blot protocol.

34-Sigma-Aldrich. (n.d.). Western Blotting Protocol (Immunoblotting Protocol).

35-Esquela-Kerscher A, Slack FJ. "Oncomirs—microRNAs with a role in cancer."

Nature Reviews Cancer. 2006;6(4):259-269.

36- Esquela-Kerscher A, Slack FJ. "Oncomirs—microRNAs with a role in cancer."

Nature Reviews Cancer. 2006;6(4):259-269.

37-Landgraf P, et al. "A mammalian microRNA expression atlas based on small RNA
library sequencing." Cell. 2007;129(7):1401-1414.

38- Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136(2), 215–233.
[Link]

39- Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature
Reviews Molecular Cell Biology, 15(8), 509–524. [Link]

40- Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are
conserved targets of microRNAs. Genome Research, 19(1), 92–105. [Link]

41-Iorio, M. V., & Croce, C. M. (2012). microRNA involvement in human cancer.

Carcinogenesis, 33(6), 1126–1133. [Link]

42- Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function,
and decay. Nature Reviews Genetics, 11(9), 597–610. [Link]

43- Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003).
Prediction of mammalian microRNA targets. Cell, 115(7), 787–798. [Link]
8674(03)01018-3

59

4 Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The
4
-
impact of microRNAs on protein output. Nature, 455(7209), 64–71.
[Link]

45- Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N.
(2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455(7209), 58–63.
[Link]

46- Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010). Mammalian microRNAs predominantly act to
decrease target mRNA levels. Nature, 466(7308), 835–840. [Link]

4 Fabian, M. R., Sonenberg, N., & Filipowicz, W. (2010). Regulation of mRNA translation
7
-
and stability by microRNAs. Annual Review of Biochemistry, 79, 351–379. [Link]
biochem-060308-103103

48- Thomson, D. W., & Dinger, M. E. (2016). Endogenous microRNA sponges: Evidence and controversy.
Nature Reviews Genetics, 17(5), 272–283. [Link]

49- Ebert, M. S., & Sharp, P. A. (2012). Roles for microRNAs in conferring robustness to biological processes.
Cell, 149(3), 515–524. [Link]

50- Pasquinelli, A. E. (2012). MicroRNAs and their targets: Recognition, regulation and
an emerging reciprocal relationship. Nature Reviews Genetics, 13(4), 271–282. [Link]

5 Helwak, A., Kudla, G., Dudnakova, T., & Tollervey, D. (2013). Mapping the human
1
-
miRNA interactome by CLASH reveals frequent noncanonical binding. Cell, 153(3), 654–665.
[Link]

52- Rajewsky, N. (2006). microRNA target predictions in animals. Nature Genetics, 38(Suppl), S8–S13.
[Link]

53- Agarwal, V., Bell, G. W., Nam, J. W., & Bartel, D. P. (2015). Predicting
effective microRNA target sites in mammalian mRNAs. eLife, 4, e05005. [Link]

54- Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., ... & Rajewsky, N.
(2005). Combinatorial microRNA target predictions. Nature Genetics, 37(5), 495–500.
[Link]

55- Vasudevan, S., Tong, Y., & Steitz, J. A. (2007). Switching from repression to activation:
MicroRNAs can up-regulate translation. Science, 318(5858), 1931–1934. [Link]

60
61